-

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.

The webcast and conference call will be hosted by Carrie Cox, Organon’s Executive Board Chair; Joe Morrissey, Interim Chief Executive Officer; and Matt Walsh, Chief Financial Officer.

IPR&D and Milestones

The company will not record any milestone expense in the third quarter of 2025.

Accessing Third Quarter 2025 Financial Results Webcast

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144 (U.S. and Canada Toll-Free) or (646) 968-2525 and using the access code Conference ID: 1036555#.

About Organon

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Contacts

Organon Media Contacts:

Felicia Bisaro
(646) 703-1807

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB

Release Summary
Organon to announce Q3 2025 financial results on November 10, 2025.
Release Versions

Contacts

Organon Media Contacts:

Felicia Bisaro
(646) 703-1807

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Social Media Profiles
More News From Organon & Co.

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups...

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will...

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Dermatology to present new Phase 3 analysis of VTAMA eczema data at the Society for Pediatric Dermatology annual meeting on July 23, 2026....
Back to Newsroom